The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
Open accessAbstract
BACKGROUND: Genetic variability among patients plays an important role in determining the dose of warfarin that should be used when oral anticoagulation is initiated, but practical methods of using genetic information have not been evaluated in a diverse and large population. We developed and used an algorithm for estimating the appropriate warfarin dose that is based on both clinical and genetic data from a broad population base. METHODS: Clinical and genetic data from 4043 patients were used to create a dose algorithm that was based on clinical variables only and an algorithm in which genetic information was added to the clinical variables. In a validation cohort of 1009 subjects, we evaluated the potential clinical value of each algorithm by calculating the percentage of patients whose predicted dose of warfarin was within 20% of the actual stable therapeutic dose; we also evaluated other clinically relevant indicators. RESULTS: In the validation cohort, the pharmacogenetic algorithm accurately identified larger proportions of patients who required 21 mg of warfarin or less per week and of those who required 49 mg or more per week to achieve the target international normalized ratio than did the clinical algorithm (49.4% vs. 33.3%, P<0.001, among patients requiring < or = 21 mg per week; and 24.8% vs. 7.2%, P<0.001, among those requiring > or = 49 mg per week). CONCLUSIONS: The use of a pharmacogenetic algorithm for estimating the appropriate initial dose of warfarin produces recommendations that are significantly closer to the required stable therapeutic dose than those derived from a clinical algorithm or a fixed-dose approach. The greatest benefits were observed in the 46.2% of the population that required 21 mg or less of warfarin per week or 49 mg or more per week for therapeutic anticoagulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885
Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L., Blough, D. K., Thummel, K. E., Veenstra, D. L., & Rettie, A. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044503 · Cited by 1,399
Systematic overview of warfarin and its drug and food interactions
Holbrook, A. M. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1095 · Cited by 1,160
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
Rost, S., Fregin, A., Ivaskevicius, V., Conzelmann, E., Hörtnagel, K., Pelz, H.-J., Lappegard, K., Seifried, E., Scharrer, I., Tuddenham, E. G. D., et al. (2004) · Nature · doi:10.1038/nature02214 · Cited by 1,134
Sconce, E. A., Khan, T. I., Wynne, H. A., Avery, P., Monkhouse, L., King, B. P., Wood, P., Kesteven, P., Daly, A. K., & Kamali, F. (2005) · Blood · doi:10.1182/blood-2005-03-1108 · Cited by 947
Anderson, J. L., Horne, B. D., Stevens, S. M., Grove, A. S., Barton, S., Nicholas, Z. P., Kahn, S. F. S., May, H. T., Samuelson, K. M., Muhlestein, J. B., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.737312 · Cited by 727
D'Andrea, G., D'Ambrosio, R. L., Di Perna, P., Chetta, M., Santacroce, R., Brancaccio, V., Grandone, E., & Margaglione, M. (2005) · Blood · doi:10.1182/blood-2004-06-2111 · Cited by 699
Medication Use Leading to Emergency Department Visits for Adverse Drug Events in Older Adults
Budnitz, D. S., Shehab, N., Kegler, S. R., & Richards, C. L. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-11-200712040-00006 · Cited by 607
Bleeding Complications With Warfarin Use: A Prevalent Adverse Effect Resulting in Regulatory Action
Wysowski, D. K., Nourjah, P., & Swartz, L. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.13.1414 · Cited by 547
CYP4F2 genetic variant alters required warfarin dose
Caldwell, M. D., Awad, T., Johnson, J. A., Gage, B. F., Falkowski, M., Gardina, P., Hubbard, J., Turpaz, Y., Langaee, T. Y., Eby, C., et al. (2008) · Blood · doi:10.1182/blood-2007-11-122010 · Cited by 521
Common VKORC1 and GGCX polymorphisms associated with warfarin dose
Wadelius, M., Chen, L. Y., Downes, K., Ghori, J., Hunt, S., Eriksson, N., Wallerman, O., Melhus, H., Wadelius, C., Bentley, D., et al. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500313 · Cited by 468
Association of warfarin dose with genes involved in its action and metabolism
Wadelius, M., Chen, L. Y., Eriksson, N., Bumpstead, S., Ghori, J., Wadelius, C., Bentley, D., McGinnis, R., & Deloukas, P. (2007) · Human Genetics · doi:10.1007/s00439-006-0260-8 · Cited by 390
Takahashi, H., Wilkinson, G. R., Nutescu, E. A., Morita, T., Ritchie, M. D., Scordo, M. G., Pengo, V., Barban, M., Padrini, R., Ieiri, I., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000184955.08453.a8 · Cited by 376
Caraco, Y., Blotnick, S., & Muszkat, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100316 · Cited by 360
AQUILANTE, C., LANGAEE, T., LOPEZ, L., YARANDI, H., TROMBERG, J., MOHUCZY, D., GASTON, K., WADDELL, C., CHIRICO, M., & JOHNSON, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.11.011 · Cited by 266
Genetic-based dosing in orthopedic patients beginning warfarin therapy
Millican, E. A., Lenzini, P. A., Milligan, P. E., Grosso, L., Eby, C., Deych, E., Grice, G., Clohisy, J. C., Barrack, R. L., Burnett, R. S. J., et al. (2007) · Blood · doi:10.1182/blood-2007-01-069609 · Cited by 178
A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance
Loebstein, R., Dvoskin, I., Halkin, H., Vecsler, M., Lubetsky, A., Rechavi, G., Amariglio, N., Cohen, Y., Ken-Dror, G., Almog, S., et al. (2007) · Blood · doi:10.1182/blood-2006-08-038984 · Cited by 171
Kimura, R., Miyashita, K., Kokubo, Y., Akaiwa, Y., Otsubo, R., Nagatsuka, K., Otsuki, T., Okayama, A., Minematsu, K., Naritomi, H., et al. (2007) · Thrombosis Research · doi:10.1016/j.thromres.2006.09.007 · Cited by 167
Evaluation of Genetic Factors for Warfarin Dose Prediction
Caldwell, M. D., Berg, R. L., Zhang, K. Q., Glurich, I., Schmelzer, J. R., Yale, S. H., Vidaillet, H. J., Jr., & Burmester, J. K. (2007) · Clinical Medicine & Research · doi:10.3121/cmr.2007.724 · Cited by 155
Tham, L. S., Goh, B. C., Nafziger, A. N., GUO, J., WANG, L., Soong, R., & Lee, S. M. L. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.06.009 · Cited by 148
Harrington, D. J., Underwood, S., Morse, C., Shearer, M. J., Tuddenham, E. G. D., & Mumford, A. D. (2004) · Thrombosis and Haemostasis · doi:10.1160/th04-08-0540 · Cited by 121
Warfarin Response and Vitamin K Epoxide Reductase Complex 1 in African Americans and Caucasians
Schelleman, H., Chen, Z., Kealey, C., Whitehead, A. S., Christie, J. D., Price, M., Brensinger, C. M., Newcomb, C. W., Thorn, C. F., Samaha, F. F., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100144 · Cited by 109
Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans
Kimmel, S. E., Christie, J. D., Kealey, C., Chen, Z., Price, M., Thorn, C. F., Brensinger, C. M., Newcomb, C. W., & Whitehead, A. S. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500445 · Cited by 87
Factors Influencing Warfarin Dose Requirements in African–Americans
Momary, K. M., Shapiro, N. L., Viana, M. A. G., Nutescu, E. A., Helgason, C. M., & Cavallari, L. H. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.11.1535 · Cited by 76
Pharmacogenomics — Ready for Prime Time?
Shurin, S. B., & Nabel, E. G. (2008) · New England Journal of Medicine · doi:10.1056/nejme0800801 · Cited by 70
McWilliam, A., Lutter, R., & Nardinelli, C. (2008) · Personalized Medicine · doi:10.2217/17410541.5.3.279 · Cited by 34
Cited by
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
Model Inversion Attacks that Exploit Confidence Information and Basic Countermeasures
Fredrikson, M., Jha, S., & Ristenpart, T. (2015) · Proceedings of the 22nd ACM SIGSAC Conference on Computer and Communications Security · doi:10.1145/2810103.2813677 · Cited by 2,961
Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw313 · Cited by 1,403
Metadata
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-02-19
- Volume
- 360
- Issue
- 8
- Pages
- 753-764
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1515782956
- Cited by
- 1,577
- References
- 26
- FWCI
- 157.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.